Medicenna TherapeuticsMDNAF +9.49%29 PB Ratio is 13.68 as of Jul. 02, 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Medicenna Therapeutics ranks worse than 89.66% on this metric.
The historical rank and industry rank for Medicenna Therapeutics's PB Ratio or its related term are showing as below:
MDNAF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 15.4
Current: 15.05
During the past 12 years, Medicenna Therapeutics's highest PB Ratio was 15.40. The lowest was 0.00. And the median was 0.00.
MDNAF's PB Ratio is ranked worse than 89.66% of 1228
companies
in the Biotechnology industry
Industry Median: 2.95
vs MDNAF: 15.05
During the past 12 months, Medicenna Therapeutics's average Book Value Per Share Growth Rate was -87.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -58.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.50% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Medicenna Therapeutics was 100.80% per year. The lowest was -64.70% per year. And the median was -18.20% per year.
Back to Basics: PB Ratio
Medicenna Therapeutics (OTCPK:MDNAF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Medicenna Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicenna Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medicenna Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medicenna Therapeutics (MDNAF) has a PB Ratio of 13.68 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medicenna Therapeutics and its competitors. According to the industry distribution chart, Medicenna Therapeutics ranks #1101 out of 1228 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Medicenna Therapeutics' PB Ratio too high?
Medicenna Therapeutics' current PB Ratio is 13.68. The Biotechnology industry median PB Ratio is 2.95. Medicenna Therapeutics' value of 13.68 is 363.7% above this industry median. Based on the distribution chart, Medicenna Therapeutics ranks #1101 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medicenna Therapeutics ranks #1101 out of 1228 companies for PB Ratio. This places Medicenna Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.95. Medicenna Therapeutics' value of 13.68 is 363.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicenna Therapeutics's current PB Ratio of 13.68 is 363.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medicenna Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicenna Therapeutics's current PB Ratio is 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current PB Ratio of 13.68. The current PB Ratio is 13.68 and 363.7% above the Biotechnology industry median of 2.95. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current PB Ratio is 13.68 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score
Get the complete analysis for MDNAF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNAF has been successfully added to your 
